KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Fulgent Genetics (FLGT) EBT Margin (2016 - 2025)

Fulgent Genetics' EBT Margin history spans 11 years, with the latest figure at 38.98% for Q4 2025.

  • For Q4 2025, EBT Margin fell 1189.0% year-over-year to 38.98%; the TTM value through Dec 2025 reached 2.56%, down 74.0%, while the annual FY2025 figure was 2.56%, 75.0% down from the prior year.
  • EBT Margin for Q4 2025 was 38.98% at Fulgent Genetics, up from 8.93% in the prior quarter.
  • Across five years, EBT Margin topped out at 74.34% in Q1 2021 and bottomed at 329.18% in Q4 2022.
  • The 5-year median for EBT Margin is 3.63% (2022), against an average of 13.03%.
  • The largest annual shift saw EBT Margin plummeted -38911bps in 2022 before it surged 25680bps in 2024.
  • A 5-year view of EBT Margin shows it stood at 59.93% in 2021, then plummeted by -649bps to 329.18% in 2022, then surged by 37bps to 205.94% in 2023, then surged by 125bps to 50.87% in 2024, then fell by -23bps to 38.98% in 2025.
  • Per Business Quant, the three most recent readings for FLGT's EBT Margin are 38.98% (Q4 2025), 8.93% (Q3 2025), and 26.31% (Q2 2025).